



MEDIA RELEASE

For immediate release on 19 June 2023

Anthony Nolan announces partnership with bioprocessing innovator MicrofluidX

Anthony Nolan Cell Therapy and Laboratory Services is delighted to announce their newest partnership with start-up MicrofluidX.

MicrofluidX will be developing its bioprocessing technology using high-quality, ethically sourced starting material from healthy adult donors. The cells provided by Anthony Nolan will be used to validate MicrofluidX's proprietary technology for the purposes of cell and gene therapy process development and manufacturing.

The results will allow MicrofluidX to demonstrate the potential benefits that their technology can bring to accelerate development and translation of new cell and gene therapies to clinical trials, at a fraction of the cost that current tools can enable. This will help accelerate the development of new treatments and make them more accessible, particularly for patients from marginalised backgrounds who may have fewer pathways available to them.

Anthony Nolan established the world's first stem cell register in 1974. Since then, the organisation has grown to support research and development of new therapies to improve patient outcomes and quality of life. Its Cell Therapy and Laboratory Services have become renowned for its sourcing and supply of donor starting materials to the cell and gene therapy industry. With an extensive list of global clients, Anthony Nolan is helping to transform the life sciences industry and its researchers to unlock new treatments, including personalised medicines.

MicrofluidX is a UK based developer of the Cyto Engine™ an innovative bioreactor platform designed to address the disconnects between cell biology research and industrialised cell therapy manufacturing. Using principles of microfluidics, the Cyto Engine™ bioreactors seamlessly scale from small volume research tools to GMP manufacturing capabilities, accelerating the development of next generation cell and gene therapies.

Daniel Gibson, Director of Cell & Gene Therapy Services at Anthony Nolan, says:

“Our partnership with MicrofluidX represents a major step in achieving our organisational aim of equity. Our work looks to ensure all patients have the best access to treatment for blood cancers or blood disorders, regardless of background or circumstance. We are optimistic and excited at the prospect of more cost-effective therapies resulting from MicrofluidX's research, making treatment more accessible for all.”

Antoine Espinet, CEO at MicrofluidX, says:

“By partnering with Anthony Nolan we know that the cells we are using to develop our technologies are ethically sourced and of the highest quality. As we begin testing the Cyto Engine™'s capabilities with our early access partners manufacturing processes we knew we needed a reliable partner to supply the starting material. We're very excited to work with the expert team at Anthony Nolan who understand our needs completely.”

This partnership will supercharge MicrofluidX in its work to address two of the biggest challenges in the field, ultra-high manufacturing costs and scalability. The cells provided by Anthony Nolan



saving the lives
of people with
blood cancer

for use in this research will be donated by healthy adult donors, who consented to donate their cells for research and manufacturing.

- ENDS -

For more information, please call the Anthony Nolan press office on 0207 424 1300 or email press@anthonymolan.org. For urgent out of hours media enquiries, call 07881 265 285.

NOTES TO EDITORS

About Anthony Nolan Cell & Gene Services

Anthony Nolan is one of the world's foremost authorities on the sourcing and supply of donor starting materials to the cell and gene therapy industry.

Clients of Anthony Nolan Cell & Gene Services are transforming the world of medicine; aiming to save and improve the lives of millions of people. The organisation is proud to play its part in this important work with first-class Cell and Gene Therapy Services. Find out more at www.anthonynolan.org/cellandgene

About Anthony Nolan

Anthony Nolan saves the lives of people with blood cancer. The charity uses its register to match potential stem cell donors to blood cancer and blood disorder patients in need of stem cell transplants. It also carries out pioneering research to increase stem cell transplant success and supports patients through their transplant journeys. Everyday Anthony Nolan gives three people a second chance at life. Find out more at www.anthonynolan.org

Note to sub editors

Please note that Anthony Nolan changed its name in 2001 and is no longer known as Anthony Nolan Trust.

About MicrofluidX

MicrofluidX is an advanced therapy manufacturing platform company based in the Stevenage Bioscience Catalyst, UK. It is developing the Cyto Engine™, a proprietary next generation, scalable bioprocessing platform for cell and gene therapy manufacture. Its mission is to make precision medicines accessible to patients around the world by disrupting the current advanced therapy development process, providing scalable, fully automated platforms that can be used in research and taken through to large-scale GMP manufacture. For more information visit www.microfluidx.co.uk or follow us on LinkedIn or Twitter